Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A method of inhibiting thrombin-induced platelet or other cell activation mediated by cleavage of a thrombin receptor on said cells comprising administering to an individual in need of such treatment an effective amount of a compound comprising one or more segments having the amino acid sequence X₁-Arg-Pro-Pro-X₂, wherein the compound has a formula selected from the group consisting of:

$$L-(X_1-Arg-Pro-Pro-X_2)_n$$
;

wherein:

 X_1 , which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids;

 X_2 , which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids, provided that the N-terminal amino acid of X_2 is not glycine;


L is a linker comprising a covalent bond or chemical group; and n is an integer from two to twenty.

- 2. (original) The method of claim 1 wherein X_1 is zero to seven amino acids and X_2 is zero to nine amino acids.
- 3. (currently amended) The method of claim 1 wherein X₁ is from zero to thirty amino acids from amino acids 1-30 of SEQ ID NO:1. zero amino acids, SEQ ID NO:1, or a fragment of SEQ ID NO:1.
- 4. (original) The method of claim 2 wherein X_1 is from zero to seven amino acids from amino acids 24-30 of SEQ ID NO:1.

PHIP\374260\2

- 5. (original) The method of claim 1 wherein the compound comprises two or more segments and at least two of the segments are different.
- 6. (original) The method of claim 1 wherein the compound comprises two or more segments and all the segments are identical.
 - 7. (original) The method of claim 1 wherein n is an integer from two to four.
 - 8. (original) The method of claim 1 wherein the compound has the formula $L-(Arg-Pro-Pro-X_2)_n$.
 - 9. (original) The method of claim 8 wherein the compound has the formula L-(Arg-Pro-Pro)_n.
- 10. (original) The method of claim 1 wherein the compound is selected from the group consisting of:
 - (a) Arg-Pro-Pro;
 - (b) Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6);
 - (c) Arg-Pro-Pro-Lys
 Arg-Pro-Pro-Asp; and

(d)



- 11. (canceled)
- 12. (canceled)
- 13. (canceled)
- 14. (currently amended) A method for preventing thrombin-induced platelet aggregation mediated by cleavage of a thrombin receptor on said platelets comprising administering to an individual in need of such treatment an effective amount of a compound comprising one or more segments having the amino acid sequence X₁-Arg-Pro-Pro-X₂, wherein the compound has a formula selected from the group consisting of:

$$L-(X_1-Arg-Pro-Pro-X_2)_n$$
;

wherein:

X₁, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids;

 X_2 , which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids, provided that the N-terminal amino acid of X_2 is not glycine;


L is a linker comprising a covalent bond or chemical group; and n is an integer from two to twenty.

15. (original) The method of claim 14 wherein X_1 is zero to seven amino acids and X_2 is zero to nine amino acids.

- 16. (currently amended) The method of claim 14 wherein X₁ is from zero to thirty amino acids from amino acids 1-30 of SEQ ID NO:1. zero amino acids, SEQ ID NO:1, or a fragment of SEQ ID NO:1.
- 17. (original) The method of claim 15 wherein X_1 is from zero to seven amino acids from amino acids 24-30 of SEQ ID NO:1.
- 18. (original) The method of claim 14 wherein the compound comprises two or more segments and at least two of the segments are different.
- 19. (original) The method of claim 14 wherein the compound comprises two or more segments and all the segments are identical.
 - 20. (original) The method of claim 14 wherein n is an integer from two to four.
 - 21. (original) The method of claim 14 wherein the compound has the formula L-(Arg-Pro-Pro-X₂)_n.
 - 22. (original) The method of claim 21 wherein the compound has the formula L-(Arg-Pro-Pro)_n.

- 23. (original) The method of claim 14 wherein the compound is selected from the group consisting of:
 - (a) Arg-Pro-Pro;
 - (b) Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6);
 - (c) Arg-Pro-Pro-Lys
 Arg-Pro-Pro-Asp; and

(d)



24. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound comprising Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6) or one or more segments having the amino acid sequence X_1 -Arg-Pro-Pro- X_2 , wherein the compound has a formula

$$L-(X_1-Arg-Pro-Pro-X_2)_n$$
;


wherein:

 X_1 , which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids;


 X_2 , which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids, provided that the N-terminal amino acid of X_2 is not glycine;

L is a linker comprising a covalent bond or chemical group; and n is an integer from two to twenty.

25. (previously presented) The pharmaceutical composition of claim 24 comprising a pharmaceutically acceptable carrier and a compound having a formula selected from the group consisting of:



(b)



- 26. (withdrawn) A method for identifying compounds that selectively inhibit thrombin-induced platelet and other cell activation comprising measuring the ability of the compounds to bind to the thrombin cleavage site on the thrombin receptor.
 - 27. (withdrawn) The method of claim 26 wherein the compounds are present in a combinatorial library.
 - 28. (withdrawn) The method of claim 26 further comprising:
 - (a) measuring the ability of the compounds to inhibit thrombin-induced platelet aggregation; and
 - (b) measuring the ability of the compounds to inhibit thrombin-induced calcium mobilization in fibroblasts.